Karen Tkach Tuzman

2 months ago | biocentury.com | Karen Tkach Tuzman

ARTICLE | Politics, Policy & LawFour main types: topic-based grant cancellation, overhead funding reduction, clawbacks from individual universities, and cuts to NIH By Karen Tkach Tuzman, Director of Biopharma IntelligenceThe Trump administration has broken with decades of bipartisan support for biomedical research, launching a coordinated effort to shrink NIH’s grantmaking portfolio, curtail intramural research and reorient priorities.

Mar 27, 2025 | biocentury.com | Karen Tkach Tuzman

ARTICLE | Emerging Company Profile The Massachusetts-based company launched a microRNA-based liquid biopsy test for endometriosis, with an eye toward disease monitoring and drug development By Karen Tkach Tuzman, Director of Biophrama Intelligence Heranova thinks the similarities between endometriosis and cancer will make the notoriously difficult-to-diagnose disease amenable to non-invasive detection via liquid biopsy of nucleic acids from uterine lining cells undergoing excessive growth,...

Mar 19, 2025 | biocentury.com | Karen Tkach Tuzman

ARTICLE | Product DevelopmentWith clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal By Karen Tkach Tuzman, Director of Biopharma IntelligenceTempus thinks it has the scale of data needed to deliver on the idea that the next era of precision medicine will go beyond single biomarkers to provide more holistic views of patients and their predicted responses to drugs.

Mar 6, 2025 | biocentury.com | Karen Tkach Tuzman

ARTICLE | Product DevelopmentWith a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey By Karen Tkach Tuzman, Director of Biopharma IntelligenceWhile most radiopharma companies are focused on a particular radioisotope platform or ligand modality, Telix is using a range of technologies to tailor therapeutic-diagnostic pairs for specific indications.

Feb 21, 2025 | biocentury.com | Karen Tkach Tuzman

ARTICLE | Editor's Commentary As human data are poised to deliver causal targets and more precise interventions, caving to anti-DEI rhetoricin science is a costly mistake By Karen Tkach Tuzman, Director of Biopharma Intelligence Amid the Trump administration’s looming threats to slash NIH and its funding of academic institutions, there is a subtler but no less disruptive shift permeating translational research — the growing sense among U.S. investigators that they will be punished for...